Key result
Double product adds no predictive value over SBP for cardiovascular mortality.
Why the study?
The prognostic value of the double product, an index of myocardial oxygen consumption, in the general population remains unknown.
Does the double product (DP) improve cardiovascular risk stratification beyond systolic blood pressure and pulse rate in the general population?
Cohort (n=9,937)
Yes
Does the double product (DP) improve cardiovascular risk stratification beyond systolic blood pressure and pulse rate in the general population?
Answers are grounded in this paper and cite their sources.
In the general population, the double product (systolic blood pressure multiplied by pulse rate) does not provide additional prognostic value for cardiovascular risk stratification beyond systolic blood pressure and pulse rate alone.
BACKGROUND: The double product (DP), consisting of the systolic blood pressure (SBP) multiplied by the pulse rate (PR), is an index of myocardial oxygen consumption, but its prognostic value in the general population remains unknown. METHODS: We recorded health outcomes in 9,937 subjects (median age, 53.2 years; 47.3% women) randomly recruited from 11 populations and enrolled in the International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) study. We obtained the SBP, PR, and DP for these subjects as determined through 24-hour ambulatory monitoring. RESULTS: Over a median period of 11.0 years, 1,388 of the 9,937 study subjects died, of whom 536 and 794, respectively, died of cardiovascular (CV) and non-CV causes, and a further 1,161, 658, 494, and 465 subjects, respectively, experienced a CV, cardiac, coronary, or cerebrovascular event. In multivariate-adjusted Cox models, not including SBP and PR, DP predicted total, CV, and non-CV mortality (standardized hazard ratio [HR], ≥ 1.10; P ≤ 0.02), and all CV, cardiac, coronary, and stroke events (HR, ≥ 1.21; P < 0.0001). For CV mortality (HR, 1.34 vs. 1.30; P = 0.71) and coronary events (1.28 vs. 1.21; P = 0.26), SBP and the DP were equally predictive. As compared with DP, SBP was a stronger predictor of all CV events (1.39 vs. 1.27; P = 0.002) and stroke (1.61 vs. 1.36; P < 0.0001), and a slightly stronger predictor of cardiac events (1.32 vs. 1.22; P = 0.06). In fully adjusted models, including both SBP and PR, the predictive value of DP disappeared for fatal endpoints (P ≥ 0.07), coronary events (P = 0.06), and stroke (P = 0.12), or DP was even inversely associated with the risk of all CV and cardiac events (both P ≤ 0.01). CONCLUSION: In the general population, we did not observe DP to add to risk stratification over and beyond SBP and PR.
No takes yet. Share an insight, caveat, or question.
Schutte et al. (2013) conducted a cohort in General population (n=9,937). Double product (systolic blood pressure multiplied by pulse rate) vs. Systolic blood pressure alone was evaluated on Cardiovascular mortality (comparing predictive value of double product vs systolic blood pressure) (HR 1.30, p=0.71). The double product was equally predictive as systolic blood pressure for cardiovascular mortality but did not add to risk stratification in fully adjusted models.
Synapse has enriched 10 related papers. Consider them for comparative context: